Pico-Tesla To File De Novo 510(k) In 2011 To Treat Parkinson's With Magnets
This article was originally published in The Gray Sheet
Executive Summary
Pico-Tesla Magnetic Therapies plans to submit a de novo 510(k) application in early 2011 to treat Parkinson's disease symptoms with a low-level electromagnetic field, according to the company
You may also be interested in...
Pico-Tesla plans atrial fibrillation trial
Pico-Tesla will begin a U.S. clinical trial of its Resonator electromagnetic field generator to treat paroxysmal atrial fibrillation in the fourth quarter, according to the company. Clinical trials are already ongoing for use of the device to create low-level electromagnetic fields (EMF) to treat Parkinson's disease and type-2 diabetes. In May, a dog study at the University of Oklahoma's Heart Rhythm Institute suggested EMF fields from the device can terminate and prevent atrial fibrillation. The so-called Magneceutical therapy system comprises two large magnetic coils; patients sit between the coils for treatment (1"The Gray Sheet" Nov. 9, 2009)
Pico-Tesla plans atrial fibrillation trial
Pico-Tesla will begin a U.S. clinical trial of its Resonator electromagnetic field generator to treat paroxysmal atrial fibrillation in the fourth quarter, according to the company. Clinical trials are already ongoing for use of the device to create low-level electromagnetic fields (EMF) to treat Parkinson's disease and type-2 diabetes. In May, a dog study at the University of Oklahoma's Heart Rhythm Institute suggested EMF fields from the device can terminate and prevent atrial fibrillation. The so-called Magneceutical therapy system comprises two large magnetic coils; patients sit between the coils for treatment (1"The Gray Sheet" Nov. 9, 2009)
Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar
FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis